KR101799113B1 - 올리고머를 함유하는 치환된 방향족 트리아진 화합물 - Google Patents

올리고머를 함유하는 치환된 방향족 트리아진 화합물 Download PDF

Info

Publication number
KR101799113B1
KR101799113B1 KR1020117026044A KR20117026044A KR101799113B1 KR 101799113 B1 KR101799113 B1 KR 101799113B1 KR 1020117026044 A KR1020117026044 A KR 1020117026044A KR 20117026044 A KR20117026044 A KR 20117026044A KR 101799113 B1 KR101799113 B1 KR 101799113B1
Authority
KR
South Korea
Prior art keywords
group
oligomer
alkyl
substituted aromatic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117026044A
Other languages
English (en)
Korean (ko)
Other versions
KR20120015311A (ko
Inventor
제니퍼 릭스-소티어
보-량 뎅
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20120015311A publication Critical patent/KR20120015311A/ko
Application granted granted Critical
Publication of KR101799113B1 publication Critical patent/KR101799113B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117026044A 2009-05-13 2010-05-13 올리고머를 함유하는 치환된 방향족 트리아진 화합물 Active KR101799113B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17793109P 2009-05-13 2009-05-13
US61/177,931 2009-05-13
PCT/US2010/034770 WO2010132691A1 (en) 2009-05-13 2010-05-13 Oligomer-containing substituted aromatic triazine compounds

Publications (2)

Publication Number Publication Date
KR20120015311A KR20120015311A (ko) 2012-02-21
KR101799113B1 true KR101799113B1 (ko) 2017-11-17

Family

ID=42557491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026044A Active KR101799113B1 (ko) 2009-05-13 2010-05-13 올리고머를 함유하는 치환된 방향족 트리아진 화합물

Country Status (10)

Country Link
US (4) US8772479B2 (enExample)
EP (1) EP2430003B1 (enExample)
JP (1) JP5656980B2 (enExample)
KR (1) KR101799113B1 (enExample)
CN (1) CN102421763B (enExample)
AU (1) AU2010248943B2 (enExample)
CA (1) CA2760219C (enExample)
IL (1) IL216314B (enExample)
MX (1) MX2011012044A (enExample)
WO (1) WO2010132691A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012044A (es) 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
JP6884703B2 (ja) 2015-02-25 2021-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 障害を治療するための5ht作動薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043772A2 (en) * 2000-11-30 2002-06-06 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
WO2006027711A2 (en) * 2004-08-26 2006-03-16 Nicholas Piramal India Limited Prodrugs and codrugs containing bio- cleavable disulfide linkers
WO2006047372A2 (en) * 2004-10-25 2006-05-04 Seradyn, Inc. Lamotrigine analogs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49823B1 (en) 1979-06-01 1985-12-25 Wellcome Found 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
RS53279B (sr) 2003-12-16 2014-08-29 Nektar Therapeutics Monodisperzne smeše pegilisanog naloksola
FR2869907B1 (fr) 2004-05-05 2009-02-13 Fabre Pierre Dermo Cosmetique Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
MX2011012044A (es) 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043772A2 (en) * 2000-11-30 2002-06-06 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
WO2006027711A2 (en) * 2004-08-26 2006-03-16 Nicholas Piramal India Limited Prodrugs and codrugs containing bio- cleavable disulfide linkers
WO2006047372A2 (en) * 2004-10-25 2006-05-04 Seradyn, Inc. Lamotrigine analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Justyna Ławecka 외 3명. Tetrahedron Letters. Vol. 49, 2008년, pp. 723-726*

Also Published As

Publication number Publication date
CN102421763B (zh) 2015-06-17
EP2430003A1 (en) 2012-03-21
KR20120015311A (ko) 2012-02-21
US20140256732A1 (en) 2014-09-11
CA2760219C (en) 2016-08-16
US20150065706A1 (en) 2015-03-05
CA2760219A1 (en) 2010-11-18
AU2010248943B2 (en) 2015-05-21
IL216314A0 (en) 2012-01-31
MX2011012044A (es) 2011-12-14
EP2430003B1 (en) 2019-02-27
US9266845B2 (en) 2016-02-23
JP5656980B2 (ja) 2015-01-21
AU2010248943A1 (en) 2011-11-10
US20160194294A1 (en) 2016-07-07
IL216314B (en) 2018-05-31
CN102421763A (zh) 2012-04-18
US9617228B2 (en) 2017-04-11
US8772479B2 (en) 2014-07-08
JP2012526847A (ja) 2012-11-01
US8895553B2 (en) 2014-11-25
US20120122871A1 (en) 2012-05-17
WO2010132691A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
KR101561707B1 (ko) 올리고머―항히스타민제 컨주게이트
WO2012083153A1 (en) Oligomer-containing apremilast moiety compounds
US9399033B2 (en) Oligomer-containing pyrrolidine compounds
US10265411B2 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
KR101799113B1 (ko) 올리고머를 함유하는 치환된 방향족 트리아진 화합물
WO2009054916A2 (en) Oligomer conjugates of lidocaine and its derivatives
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物
US9540330B2 (en) Oligomer-containing hydantoin compounds
EP2400989B1 (en) Gabapentin-peg conjugates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9